factually
Index/Topics/CBD and DOAC Interaction Risk

CBD and DOAC Interaction Risk

The interaction risk between cannabidiol (CBD) and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran, including the potential for CBD to alter DOAC exposure and bleeding risk.

Fact-Checks

1 result
Jan 16, 2026

What are the documented clinical case reports of CBD causing adverse events in patients on DOACs, if any, since 2023?

A targeted review of the supplied literature finds no published clinical case reports since 2023 that directly document cannabidiol (CBD) causing an adverse event specifically in a patient taking a di...